Name | N-{trans-4-[2-(6-Cyano-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]cyclohexyl}-4-quinolinecarboxamide dihydrochloride |
---|---|
Synonyms |
N-{trans-4-[2-(6-Cyano-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]cyclohexyl}-4-quinolinecarboxamide dihydrochloride
4-Quinolinecarboxamide, N-[trans-4-[2-(6-cyano-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]cyclohexyl]-, hydrochloride (1:2) MFCD16627999 SB 277011A dihydrochloride |
Description | SB 277011A dihydrochloride is a potent, selective, orally bioavailable and brain penetrate dopamine D3 receptor antagonist, with pKis of 8.0, 6.0, <5.2 and 5.9 for D3, D2, 5-HT1B, and 5-HT1D receptors, respectively. |
---|---|
Related Catalog | |
Target |
pKi: 8.0 (D3 receptor), 6.0 (D2 receptor), <5.2 (5-HT1B receptor), 5.9 (5-HT1D receptor)[1] |
In Vitro | SB 277011A dihydrochloride is a potent, selective, orally bioavailable and brain penetrate dopamine D3 receptor antagonist, and restores ≥100-fold selectivity against the D2, 5-HT1B, and 5-HT1D receptors, with pKis of 8.0, 6.0, <5.2 and 5.9 for D3, D2, 5-HT1B, and 5-HT1D receptors, respectively[1]. |
In Vivo | SB 277011A (SB 277011; 3 mg/kg, p.o.) completely reverses the effects of quinelorane in the nucleus accumbens, but does not reverse the effects of quinelorane in the striatum at 93 mg/kg in rats[1]. |
References |
Molecular Formula | C28H32Cl2N4O |
---|---|
Molecular Weight | 511.486 |
Exact Mass | 510.195313 |
Storage condition | -20°C |